Exercise and biomarkers of early-stage prostate cancer – MSKCC
Memorial Sloan Kettering Cancer Center (MSKCC) shared a post on X:
“A first of its kind clinical trial led by MSK exercise scientist Dr. Lee Jones suggests that specific amounts of exercise by men with early-stage prostate cancer before surgery can meaningfully improve two key biomarkers associated with better outcomes.”
Read further.
Source: MSKCC/X
Founded in 1884 Memorial Sloan Kettering Cancer Center (MSK or MSKCC) is a renowned cancer treatment and research facility located in Manhattan, New York City. With over 120 research laboratories, it is globally recognized for its dynamic cancer research program.
MSK has pioneered numerous treatment advances, including radiation therapy, chemotherapy, immunotherapy, and precision medicine. Recent successes include the development of checkpoint inhibitors and CAR T cells.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023